U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C24H31FO6.H2O
Molecular Weight 887.0126
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUNISOLIDE

SMILES

CC1(C)O[C@]2([H])C[C@@]3([H])[C@]4([H])C[C@@]([H])(C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@]([H])(C[C@]3(C)[C@]2(C(=O)CO)O1)O)F.CC1(C)O[C@]2([H])C[C@@]3([H])[C@]4([H])C[C@@]([H])(C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@]([H])(C[C@]3(C)[C@]2(C(=O)CO)O1)O)F.O

InChI

InChIKey=MIXMJCQRHVAJIO-TZHJZOAOSA-N
InChI=1S/2C24H31FO6.H2O/c2*1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26;/h2*5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3;1H2/t2*13-,14-,16-,17-,19+,20+,22-,23-,24+;/m00./s1

HIDE SMILES / InChI

Molecular Formula C24H31FO6
Molecular Weight 434.4987
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/flunisolide.html

Flunisolide is a synthetic corticosteroid. It is administered either as an oral metered-dose inhaler for the treatment of asthma or as a nasal spray for treating allergic rhinitis. Corticosteroids are naturally occurring hormones that prevent or suppress inflammation and immune responses. When given as an intranasal spray, flunisolide reduces watery nasal discharge (rhinorrhea), nasal congestion, postnasal drip, sneezing, and itching oat the back of the throat that are common allergic symptoms. Flunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin. It is used for the maintenance treatment of asthma as a prophylactic therapy. Flunisolide is marketed as AeroBid, Nasalide, Nasarel.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
32.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FLUNISOLIDE

Approved Use

Flunisolide Nasal Solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis.

Launch Date

1.0140768E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1 ng/mL
160 μg 2 times / day multiple, respiratory
dose: 160 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
FLUNISOLIDE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.2 ng × h/mL
160 μg 2 times / day multiple, respiratory
dose: 160 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
FLUNISOLIDE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.7 h
0.5 mg single, respiratory
dose: 0.5 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUNISOLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
0.5 mg single, respiratory
dose: 0.5 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUNISOLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Other AEs: Headache, Fever...
Other AEs:
Headache (13.8%)
Fever (3.7%)
Allergic reaction (4.6%)
Pain (4.6%)
Accidental injury (3.7%)
Infection (0.9%)
Back pain (3.2%)
Vomiting (4.6%)
Dyspepsia (3.2%)
Pharyngitis (16.6%)
Rhinitis (15.7%)
Cough increased (5.5%)
Sinusitis (4.1%)
Epistaxis (0.9%)
Rash (3.7%)
Urinary tract infection (0.9%)
Sources:
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Other AEs: Headache, Fever...
Other AEs:
Headache (8.8%)
Fever (0.9%)
Allergic reaction (4.4%)
Pain (1.8%)
Accidental injury (3.5%)
Infection (0.9%)
Back pain (1.8%)
Dyspepsia (3.5%)
Pharyngitis (16.8%)
Rhinitis (3.5%)
Cough increased (1.8%)
Sinusitis (8.8%)
Rash (1.8%)
Urinary tract infection (3.5%)
Sources:
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Other AEs: Headache, Fever...
Other AEs:
Headache (9%)
Fever (6.9%)
Allergic reaction (4.2%)
Pain (2.6%)
Accidental injury (3.7%)
Infection (3.7%)
Back pain (0.5%)
Vomiting (4.2%)
Dyspepsia (2.1%)
Pharyngitis (17.5%)
Rhinitis (9%)
Cough increased (8.5%)
Sinusitis (7.4%)
Epistaxis (3.2%)
Rash (2.6%)
Urinary tract infection (1.1%)
Sources:
85 ug 2 times / day steady, respiratory
Dose: 85 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 85 ug, 2 times / day
Sources:
unhealthy, 6-11 years
n = 510
Health Status: unhealthy
Condition: asthma
Age Group: 6-11 years
Population Size: 510
Sources:
Disc. AE: Asthma, Pharyngitis...
AEs leading to
discontinuation/dose reduction:
Asthma (10%)
Pharyngitis (1.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Epistaxis 0.9%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Infection 0.9%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Urinary tract infection 0.9%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Headache 13.8%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Rhinitis 15.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Pharyngitis 16.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Back pain 3.2%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Dyspepsia 3.2%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Accidental injury 3.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Fever 3.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Rash 3.7%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Sinusitis 4.1%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Allergic reaction 4.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Pain 4.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Vomiting 4.6%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Cough increased 5.5%
160 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 160 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 160 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 217
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 217
Sources:
Fever 0.9%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Infection 0.9%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Back pain 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Cough increased 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Pain 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Rash 1.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Pharyngitis 16.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Accidental injury 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Dyspepsia 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Rhinitis 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Urinary tract infection 3.5%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Allergic reaction 4.4%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Headache 8.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Sinusitis 8.8%
320 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 320 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 320 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 113
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 113
Sources:
Back pain 0.5%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Urinary tract infection 1.1%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Pharyngitis 17.5%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Dyspepsia 2.1%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Pain 2.6%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Rash 2.6%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Epistaxis 3.2%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Accidental injury 3.7%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Infection 3.7%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Allergic reaction 4.2%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Vomiting 4.2%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Fever 6.9%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Sinusitis 7.4%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Cough increased 8.5%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Headache 9%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Rhinitis 9%
80 ug 2 times / day steady, respiratory (starting)
Recommended
Dose: 80 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 80 ug, 2 times / day
Sources:
unhealthy, 4-78 years
n = 189
Health Status: unhealthy
Condition: asthma
Age Group: 4-78 years
Sex: M+F
Population Size: 189
Sources:
Pharyngitis 1.7%
Disc. AE
85 ug 2 times / day steady, respiratory
Dose: 85 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 85 ug, 2 times / day
Sources:
unhealthy, 6-11 years
n = 510
Health Status: unhealthy
Condition: asthma
Age Group: 6-11 years
Population Size: 510
Sources:
Asthma 10%
Disc. AE
85 ug 2 times / day steady, respiratory
Dose: 85 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 85 ug, 2 times / day
Sources:
unhealthy, 6-11 years
n = 510
Health Status: unhealthy
Condition: asthma
Age Group: 6-11 years
Population Size: 510
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim
PubMed

PubMed

TitleDatePubMed
Flunisolide HFA.
2002
Nasal cellularity in 183 unselected schoolchildren aged 9 to 11 years.
2002 Dec
Multiple-dose proportionality study of flunisolide hydrofluoroalkane.
2002 Sep-Oct
A review of once-daily delivery of anti-asthmatic drugs in children.
2003 Feb
Effect of HFA-flunisolide on peripheral lung inflammation in asthma.
2003 Jul
Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation.
2003 Jul
Triple inhaled drug protocol for the treatment of acute severe asthma.
2003 Jun
Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma.
2003 Mar
Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children.
2003 Mar
Inappropriate use of anti-asthmatic drugs in the Italian paediatric population.
2003 Oct
Effect of topical nasal corticosteroids on patients with chronic fatigue syndrome and rhinitis.
2003 Sep
A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children.
2003 Sep
Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses.
2004
Safety and tolerability of treatments for allergic rhinitis in children.
2004
Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma.
2004
[Therapeutic effect of the association between pulmonary ventilation and aerosol--inhalation with sulphureous mineral water in the chronic bronchopneumopathies].
2004 Apr
Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids.
2004 Dec
Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan.
2004 Mar-Apr
Flunisolide HFA for the treatment of asthma: an old friend reformulated.
2004 May
Treatment with inhaled flunisolide.
2004 May
In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics.
2004 Sep
Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB.
2004 Sep
Effects of inhaled corticosteroids on bone.
2005 Jan
Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children.
2006
Flunisolide attenuates nitric oxide-induced DNA damage in rat trachea epithelial cells.
2006
Once-daily intranasal corticosteroids for allergic rhinitis. Examining Treatment issues.
2006 Apr
Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review.
2006 Aug
Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol.
2006 Jan 24
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats.
2006 Jan-Feb
Ciclesonide for the treatment of asthma.
2006 Mar
Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma.
2006 Mar
Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells.
2006 Mar 17
Allergic rhinitis: evidence for impact on asthma.
2006 Nov 30
Topical glucocorticosteroids in rhinitis: clinical aspects.
2006 Oct
Nebulized drug admixtures: effect on aerosol characteristics and albuterol output.
2006 Winter
A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
2007
Hypertrichosis as a side effect of inhaled steroids in children.
2007 Apr
Topical nasal steroids for intermittent and persistent allergic rhinitis in children.
2007 Jan 24
Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma.
2007 Jan-Feb
Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects.
2007 Jul
Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.
2007 Jul 25
Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency).
2007 Jul-Aug
A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience.
2007 Nov-Dec
Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat soft mist inhaler: findings from two dose-ranging studies in healthy men.
2008
New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide.
2008 Apr
Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis.
2008 Jul
The impact of generic-only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma.
2008 Jul 18
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies.
2008 Nov 4
Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications.
2008 Oct
Late development of esophageal stricture following radiation and chemotherapy for small cell carcinoma of the lung: A case report.
2008 Sep 19
Patents

Sample Use Guides

Initial dose: 2 sprays in each nostril 2 times a day. If needed, this dose may be increased to 2 sprays in each nostril 3 times a day. Maximum total daily doses should not exceed 8 sprays in each nostril.
Route of Administration: Nasal
Flunisolide at all the tested concentrations ((0.1 to 10 uM) effectively inhibited ICAM-1 expression and GM-CSF and IL-5 release. The percent inhibition induced by the highest flunisolide concentration (10 uM) for the various BEAS-2B functions was 30%, 60%, and 70%, respectively.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:03:38 UTC 2021
Edited
by admin
on Fri Jun 25 21:03:38 UTC 2021
Record UNII
QK4DYS664X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUNISOLIDE
JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
AEROSPAN
Brand Name English
AEROBID
Brand Name English
FLUNISOLIDE [ORANGE BOOK]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 6-FLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, HYDRATE (2:1), (6.ALPHA.,11.BETA.,16.ALPHA.)-
Common Name English
NASAREL
Brand Name English
RS-3999
Code English
FLUNISOLIDE HEMIHYDRATE [WHO-DD]
Common Name English
FLUNISOLIDE [JAN]
Common Name English
NASALIDE
Brand Name English
6.ALPHA.-FLUORO-11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE CYCLIC 16,17-ACETAL WITH ACETONE, HEMIHYDRATE
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 6-FLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, HEMIHYDRATE, (6.ALPHA.,11.BETA.,16.ALPHA.)-
Common Name English
FLUNISOLIDE [VANDF]
Common Name English
FLUNISOLIDE [MART.]
Common Name English
NSC-757871
Code English
FLUNISOLIDE [USAN]
Common Name English
FLUNISOLIDE [USP MONOGRAPH]
Common Name English
FLUNISOLIDE [USP-RS]
Common Name English
Classification Tree Code System Code
WHO-VATC QR01AD04
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
WHO-ATC R03BA03
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
WHO-ATC R01AD04
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
WHO-VATC QR03BA03
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
Code System Code Type Description
IUPHAR
7076
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
NCI_THESAURUS
C29054
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
EVMPD
SUB13899MIG
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
PUBCHEM
11954221
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
RXCUI
1298840
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
CAS
77326-96-6
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
FDA UNII
QK4DYS664X
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
ChEMBL
CHEMBL1512
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
WIKIPEDIA
FLUNISOLIDE
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
MESH
C007734
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
DRUG BANK
DB00180
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
RXCUI
25120
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
ALTERNATIVE
LACTMED
Flunisolide
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
DRUG CENTRAL
1201
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY
USP_CATALOG
1274505
Created by admin on Fri Jun 25 21:03:38 UTC 2021 , Edited by admin on Fri Jun 25 21:03:38 UTC 2021
PRIMARY USP-RS
Related Record Type Details
TARGET -> AGONIST
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC